Most Popular
|
Breaking News
Newsletter
|
| Cyagen and Landau Strengthen Cooperation to Accelerate the Research and Development of AI-designed AAV Gene Therapy Vectors |
| Dec 12, 2022 |
| Recently, Cyagen and Guangdong Landau Biotechnology Co., Ltd. (hereinafter referred to as "Landau Biotech") strengthened their strategic partnership on the basis of the original strategic cooperation. Read More > |
|
Research Trends
|
| A Good Helper for SARS-CoV-2 & COVID-19 Research: Selection and Application of Mouse Models |
| Dec 06, 2022 |
| Animal models have assisted researchers' understanding of COVID-19 pathogenesis and host immune response to SARS-CoV-2 infection, and are of great significance in helping the rapid development of disease preventatives, vaccines, and treatments. Read More > |
|
Research Trends
|
| Application of Flow Cytometry in Preclinical CAR-T Development |
| Nov 28, 2022 |
| Chimeric Antigen Receptor T-Cell (CAR-T) Immunotherapy uses genetic engineering technology to transform autologous or allogeneic T cells into new killer cells targeting tumor-specific antigens, by which remarkable results have been achieved in the treatment of hematological malignancies. Read More > |
|
Video
Newsletter
Breaking News
Q&A
|
| The First Artificial Chief Scientific Officer: AI Marvin |
| Nov 21, 2022 |
| Have you ever wondered what the future of science education looks like? Many envision a future of readily accessible science knowledge and facts presented by intelligent, interactive teachers. Read More > |
|
Breaking News
|
| Cyagen and Neurophth Enter Global Strategic Collaboration to Develop AI-Designed AAV Gene Therapy Vectors for Ophthalmic Disorders |
| Nov 08, 2022 |
| Cyagen today announced a strategic collaboration with Neurophth Therapeutics, Inc. to co-develop next-generation AAV gene therapy vectors for specific types of genetic ophthalmic disorders. Read More > |
|
Research Trends
|
| Animal Welfare Focus: Humane Endpoints in Rats and Mice in Tumor Research Programs |
| Nov 04, 2022 |
| In recent years, more and more people advocate the "3Rs" principle of experimental animals: Reduction, Replacement, and Refinement. Read More > |
|
Newsletter
|
| 3rd Annual Gene Therapy for Ophthalmic Disorders Meeting in Review |
| Oct 31, 2022 |
| Cyagen representatives recently attended The 3rd Annual Gene Therapy for Ophthalmic Disorders meeting with 150+ stakeholders and industry leaders in ophthalmic gene therapy. The event brought together ophthalmology experts with world-class learning tracks to address the challenges faced in the preclinical stages and in clinical development, aiming to get these drugs to the ophthalmic gene therapy patients who need them as fast as possible. Read More > |
|
Research Trends
|
| Vision Stolen by Years - Age-related Macular Degeneration |
| Oct 26, 2022 |
| Many older adults experience a noticeable loss of vision as age increases, but the inability to see fine details in the center of vision may be a sign of age-related macular degeneration (AMD). Read More > |
|
Research Trends
|
| Accelerating CAR-T Cell Therapy Research |
| Oct 13, 2022 |
| By using the body's own immune system to kill tumor cells, immune cell therapy is anticipated to be a breakthrough strategy to "cure" many types of cancer. Among them, chimeric antigen receptor T-cell immunotherapy (CAR-T) has achieved remarkable results in the treatment of various hematological malignancies. As of 2022, seven CAR-T cell therapy products have been launched globally, including three in China. Read More > |
|
Research Trends
|
| Research Progress of CAR-T Therapy in Solid Tumor Treatment |
| Sep 23, 2022 |
| CAR-T cell therapy research has developed rapidly in recent years, largely based on the remarkable efficacy of CAR-T therapy in hematological malignancies, and scientists are moving quickly to apply this innovative immunotherapy to the treatment of solid tumors, including sarcomas, carcinomas, and lymphomas. Herein, we review the background of CAR-T cell therapy in solid tumor treatment, common research targets, CAR-T optimization strategy, and clinical research progress. Read More > |
